Ovarian Neoplasms: Clinical Trials

35 trials for Ovarian Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

15 completed, 7 unknown, 4 terminated, 3 not yet recruiting. 35 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 435Completed 15, Unknown 7, Terminated 4, Not yet recruiting 3, Active not recruiting 2, Recruiting 2, Withdrawn 2

Follow Ovarian Neoplasms: new trials by email Literature Review of Ovarian Neoplasms trials Research Report on Ovarian Neoplasms

Trials (filtered) newest first · largest first

All 35 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses in Gynecologic Oncology Surgery
Indocyanine Green, Near-Infrared Fluorescence Imaging System - Gynecologic Cancers, Ovarian Cancer
Phase 4Not yet recruitingIstanbul University502027-06-012026-11-18
CYTALUX Dose Extension Study
CYTALUX (pafolacianine) injection - Cancer in the Lung, Ovarian Cancer
Phase 4Not yet recruitingOn Target Laboratories, LLC1062026-11-152026-11-09
Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
Niraparib - Ovarian Cancer
Phase 4RecruitingUniversity of Miami702026-07-282026-08-05
A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer
Niraparib - Ovarian Neoplasms
Phase 4Not yet recruitingGlaxoSmithKline672025-04-222025-03-21
OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
Olaparib, Lenvatinib, Sunitinib - Renal Cell Carcinoma, Ovarian Carcinoma
Phase 4UnknownUniversity Medical Center Groningen302024-05-012023-11-29
First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients
Olaparib, Bevacizumab - Carcinoma, Ovarian Epithelial
Phase 4Active not recruitingMario Negri Institute for Pharmacological Research1902023-09-152026-06-25
The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of Action
Propofol, Sevoflurane - Lung Cancer, Brain Tumor
Phase 4UnknownKaohsiung Medical University Chung-Ho Memorial Hospital13162023-05-232023-09-28
Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics)
Propofol 1%, Sevoflurane/Ultane - Ovarian Cancer
Phase 4RecruitingKaohsiung Medical University Chung-Ho Memorial Hospital4162022-11-232023-05-30
PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer
Niraparib - Epithelial Ovarian Cancer, Ovarian Cancer
Phase 4UnknownSeoul National University Hospital1022022-01-012022-01-26
NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients.
Pharmacokinetics, Dosage of Niraparib - Adult Patients With Platinum-sensitive, Relapsed, High Grade Serous Epithelial Ovarian Cancer
Phase 4TerminatedHospices Civils de Lyon122021-05-052025-05-22
Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy
Aspirin - Venous Thromboembolism, Ovarian Cancer
Phase 4CompletedDuke University192020-08-082022-09-26
A Study of Serum Folate Levels in Patients Treated With Olaparib
Folic Acid Tablet - Ovarian Cancer, Breast Cancer
Phase 4CompletedRush University Medical Center102020-07-212026-03-04
Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer
Olaparib - Ovarian Cancer, Breast Cancer
Phase 4CompletedAstraZeneca2022020-05-252025-03-10
NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.
Niraparib - Ovarian Cancer
Phase 4CompletedARCAGY/ GINECO GROUP1412019-04-032024-12-13
Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer
pegylated liposomal doxorubicin, paclitaxel, Carboplatin - Efficacy and Safety
Phase 4UnknownWomen's Hospital School Of Medicine Zhejiang University3962019-03-192022-07-18
An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Bevacizumab - Ovarian Neoplasms, Peritoneal Neoplasms
Phase 4CompletedHoffmann-La Roche1002018-12-052025-06-26
Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers.
Fluciclovine F18 - Cervical Cancer, Endometrial Cancer
Phase 4UnknownBital Savir-Baruch302018-11-142020-02-28
NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma
BRCA testing - Ovarian Carcinoma, Fallopian Tube Carcinoma
Phase 4Active not recruitingEuropean Institute of Oncology3232018-06-122025-05-15
Diaphragmatic Resection And Gynecological Ovarian Neoplasm
thoracic Drain Tube 24 Fr. - Ovarian Cancer
Phase 4CompletedCatholic University of the Sacred Heart882018-03-202020-05-22
Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations
apatinib - Stage IV Cancer
Phase 4UnknownSun Yat-sen University2172018-02-262020-05-12

Showing 20 of 35. Sign in to see all of them.

Narrower conditions

Breast Neoplasms (8)  ·  Carcinoma, Ovarian Epithelial (4)  ·  Endometrial Neoplasms (4)  ·  Lung Neoplasms (4)  ·  Uterine Cervical Neoplasms (4)  ·  Brain Neoplasms (2)  ·  Fallopian Tube Neoplasms (2)  ·  Neoplasms (2)  ·  Recurrence (2)  ·  Uterine Neoplasms (2)  ·  Anastomotic Leak (1)  ·  Anemia (1)  ·  Blood Loss, Surgical (1)  ·  Carcinoma, Non-Small-Cell Lung (1)

Broader conditions

Adnexal Diseases (35)  ·  Endocrine Gland Neoplasms (35)  ·  Endocrine System Diseases (35)  ·  Female Urogenital Diseases (35)  ·  Female Urogenital Diseases and Pregnancy Complications (35)  ·  Genital Diseases (35)  ·  Genital Diseases, Female (35)  ·  Genital Neoplasms, Female (35)  ·  Gonadal Disorders (35)  ·  Neoplasms by Site (35)  ·  Ovarian Diseases (35)  ·  Urogenital Diseases (35)  ·  Urogenital Neoplasms (35)  ·  Neoplasms (33)  ·  Breast Diseases (8)

Interventions

niraparib (4)  ·  Bevacizumab (3)  ·  Carboplatin (3)  ·  olaparib (3)  ·  Paclitaxel (2)  ·  Propofol (2)  ·  Saline Solution (2)  ·  Sevoflurane (2)  ·  apatinib (2)  ·  liposomal doxorubicin (2)  ·  Anesthesia, Inhalation (1)  ·  Aprepitant (1)  ·  Aspirin (1)  ·  Dexamethasone (1)  ·  Folic Acid (1)

Sponsors

Kaohsiung Medical University Chung-Ho Memorial Hospital (2)  ·  ARCAGY/ GINECO GROUP (1)  ·  Amgen (1)  ·  AstraZeneca (1)  ·  Bital Savir-Baruch (1)  ·  Catholic University of the Sacred Heart (1)  ·  Dartmouth-Hitchcock Medical Center (1)  ·  Duke University (1)  ·  Eli Lilly and Company (1)  ·  European Institute of Oncology (1)  ·  GlaxoSmithKline (1)  ·  Gynecologic Oncology Associates (1)  ·  Hoffmann-La Roche (1)  ·  Hospices Civils de Lyon (1)  ·  Istanbul University (1)

Countries

United States (9)  ·  China (4)  ·  Italy (4)  ·  France (2)  ·  India (2)  ·  Netherlands (2)  ·  Taiwan (2)  ·  Austria (1)  ·  Canada (1)  ·  Germany (1)  ·  Nigeria (1)  ·  Sweden (1)  ·  Turkey (Türkiye) (1)

Top investigators

Zhi-Fu Wu (2)  ·  Aleena Banerji, MD (1)  ·  Bital Savir-Baruch, M.D (1)  ·  Brittany Davidson, MD (1)  ·  Ciro Gallo, M.D. (1)  ·  Danielle Vicus, MD (1)  ·  Daphne Gschwantler-Kaulich, Ass.Prof.Dr. (1)  ·  Esther Broekman, MD (1)  ·  Federica Tomao (1)  ·  Francesco Perrone, M.D., Ph.D. (1)  ·  Gennaro Daniele, M.D., Ph.D. (1)  ·  Gini Fleming, MD (1)

Results publications

PMID 18165618, PMID 19383827, PMID 20118030, PMID 26947961, PMID 31216198, PMID 31586247, PMID 33931498, PMID 34462317, PMID 39415516, PMID 39673810, PMID 41709925, PMID 42575837, PMID 42851761

NIH funding

2018 (1)